Science Explorer Interactive view Map
Topic · Pharmacology

Drug-Induced Adverse Reactions

Drug-Induced Adverse Reactions is a research topic within Pharmacology. Science Explorer counts 24k research works in it since 1950. 13.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on hypersensitivity reactions to various drugs and medications, including the role of specific HLA genotypes such as HLA-B*5701, HLA-B*1502, and HLA-B*5801 in predicting severe cutaneous adverse reactions like Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. The cluster also covers topics related to drug-induced hypersensitivity syndrome (DIHS), delayed drug hypersensitivity reactions, and the use of genetic screening to prevent abacavir hypersensitivity reactions.

  • HLA-B*5701
  • Stevens-Johnson Syndrome
  • Toxic Epidermal Necrolysis
  • Drug Hypersensitivity
  • Abacavir
  • Carbamazepine
  • Allopurinol
  • DRESS Syndrome
  • Immediate Allergic Reactions
  • HLA Genotyping
Research works
24k
fractional, since 1950
In the world top 10%
3.1k
per year above
Top-10% rate
13.0%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+34%
the tick is no change

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Drug-Induced Adverse Reactions research?

By volume, the United States and China publish the most (1k and 335 works in 2022–2025).

By volume, 2022–2025

  1. 1 United States 1k works
  2. 2 China 335 works
  3. 3 India 333 works
  4. 4 Japan 224 works
  5. 5 France 194 works
  6. 6 Spain 182 works
  7. 7 United Kingdom 157 works
  8. 8 Türkiye 142 works
  9. 9 Germany 137 works
  10. 10 Italy 128 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 36.2%China: 11.7%India: 11.6%Japan: 7.8%6 others listed: 32.7%36%largest
United States1,039 · 36.2%China335 · 11.7%India333 · 11.6%Japan224 · 7.8%6 others listed940 · 32.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead Drug-Induced Adverse Reactions research?

By volume in 2022–2025, Vanderbilt University Medical Center publishes the most Drug-Induced Adverse Reactions research, followed by Sağlık Bilimleri Üniversitesi and Harvard University.

Who are the leading researchers in Drug-Induced Adverse Reactions?

The most-cited researchers publishing on Drug-Induced Adverse Reactions include Aziz Sheikh, Luigi Naldi and Trevor W. Robbins.

  1. 1 Aziz Sheikh United Kingdom 5.8k citations
  2. 2 Luigi Naldi Italy 4.7k citations
  3. 3 Trevor W. Robbins United Kingdom 3.1k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

Where is Drug-Induced Adverse Reactions research done?

The largest centres of Drug-Induced Adverse Reactions research in 2022–2025 are Paris (France), Tokyo (Japan), Madrid (Spain) and Beijing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Nashville.

Largest cities, 2022–2025

  1. 1 Paris France 61 works
  2. 2 Tokyo Japan 58 works
  3. 3 Madrid Spain 53 works
  4. 4 Beijing China 48 works
  5. 5 Boston United States 47 works
  6. 6 London United Kingdom 47 works
  7. 7 Istanbul Türkiye 44 works
  8. 8 New York United States 43 works
  9. 9 Seoul South Korea 38 works
  10. 10 Melbourne Australia 35 works

Where it is the local speciality

  1. NashvilleUS · 28.1 works7.3×
← less than its size predictsmore →

Location quotient: how much more of its research is in Drug-Induced Adverse Reactions than the world average.

See Drug-Induced Adverse Reactions on the map

Where is the best place to study Drug-Induced Adverse Reactions?

Among universities, judged by research, Harvard University, Sağlık Bilimleri Üniversitesi and Yale University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 11.22%fractional works in this node (log) →share in the world top 10% →Harvard University: 16, 24.1%Sağlık Bilimleri Üniversitesi: 16, 4.3%Yale University: 13, 13.1%University of Toronto: 8, 25.2%Chinese Academy of Medical Sciences & Peking Union Medical College: 8, 26.1%Philipps University of Marburg: 9, 4.8%All India Institute of Medical Sciences: 13, 2.9%Post Graduate Institute of Medical Education and Research: 9, 0.8%Istanbul University: 8, 4.3%University of North Carolina at Chapel Hill: 9, 6.6%University of TorontoHarvard UniversityYale UniversitySağlık Bilimleri Üni…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 Harvard UniversityUnited States 62.824.1%3.2×16 +44.3%
2 Sağlık Bilimleri ÜniversitesiTürkiye 49.64.3%7.1×16
3 Yale UniversityUnited States 40.313.1%3.2×13 +36.5%
4 University of TorontoCanada 40.125.2%1.5×8 -9.5%
5 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 35.826.1%2.1×8 -17.9%
6 Philipps University of MarburgGermany 35.44.8%9.4×9 -40.6%
7 All India Institute of Medical SciencesIndia 34.02.9%5.4×13 +71.4%
8 Post Graduate Institute of Medical Education and ResearchIndia 25.80.8%6.6×9 +69.3%
9 Istanbul UniversityTürkiye 23.64.3%5.5×8 +3.0%
10 University of North Carolina at Chapel HillUnited States 17.96.6%1.3×9 +61.4%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Drug-Induced Adverse Reactions research growing?

Output in 2018–2022 was 34% higher than in 2013–2017, peaking in 2021. The fastest-growing topics are Drug-Induced Adverse Reactions.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.